Related Experiment Videos
SOCS1 methylation in patients with newly diagnosed acute myeloid leukemia
Chien-Yuan Chen1, Woei Tsay, Jih-Luh Tang
1Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Abstract:
The proliferation and differentiation of hematopoietic precursor cells depend on various cytokines. The suppressor of cytokine signaling-1 (SOCS1) down-regulates Janus kinases/signal transducers and activators of transcription (JAK/STAT) pathway activity and inhibits the biological effects of cytokines. SOCS1 has been shown to have tumor-suppressor activity, and methylation of this gene, resulting in transcriptional silencing, has been found in 65% of hepatocellular carcinoma and has been suggested to play an important role in the development of the cancer. The methylation status of the SOCS1 gene in acute myeloid leukemia (AML) has not been reported before. In this study, we analyzed SOCS1 methylation in 89 patients with newly diagnosed AML and correlated the result with immunophenotypes, cytogenetics, clinical features, and treatment outcome. SOCS1 methylation was found in the leukemic cells from 53 patients (60%). Thirteen (76%) of the 17 patients with t(15;17) had SOCS1 methylation, whereas this gene was methylated in only one (11%) of the nine patients with t(8;21). The frequencies of SOCS1 methylation among various cytogenetic subgroups differed significantly (P = 0.014). Other clinical and laboratory parameters and the disease-free survival and overall survival were similar between patients with and without SOCS1 methylation. In conclusion, SOCS1 methylation occurs in more than half of AML cases, correlates with cytogenetic abnormalities, and may play an important role in the development of subsets of AML.
Insights
Suppressor of cytokine signaling-1 (SOCS1) gene methylation is common in acute myeloid leukemia (AML), found in 60% of patients. This methylation correlates with specific cytogenetic abnormalities but does not impact survival outcomes.
Area of Science:
- Hematology
- Molecular Biology
- Oncology
Background:
- Cytokines regulate hematopoietic precursor cell proliferation and differentiation.
- Suppressor of cytokine signaling-1 (SOCS1) inhibits the Janus kinases/signal transducers and activators of transcription (JAK/STAT) pathway.
- SOCS1 exhibits tumor-suppressor activity; its methylation and silencing are implicated in hepatocellular carcinoma development.
Purpose of the Study:
- To investigate the methylation status of the SOCS1 gene in acute myeloid leukemia (AML).
- To correlate SOCS1 methylation with immunophenotypes, cytogenetics, clinical features, and treatment outcomes in AML patients.
Main Methods:
- Analysis of SOCS1 methylation in leukemic cells from 89 newly diagnosed AML patients.
- Correlation of methylation status with patient immunophenotypes, cytogenetics, clinical characteristics, and survival data.
Main Results:
- SOCS1 methylation was detected in 53 out of 89 (60%) AML patients.
- A significant correlation was observed between SOCS1 methylation and specific cytogenetic abnormalities, notably t(15;17) and t(8;21).
- No significant differences in disease-free survival or overall survival were found between methylated and unmethylated groups.
Conclusions:
- SOCS1 methylation is a frequent event in AML, occurring in over half of the cases.
- SOCS1 methylation is associated with specific cytogenetic abnormalities in AML.
- While implicated in cancer development, SOCS1 methylation in AML does not appear to affect patient survival based on this cohort.